This inventor holds 2 USPTO granted patents. Top assignee: Zs Pharma, Inc.. Active years: 2016-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016-2019
Title: Innovations by Jeff Gilmore in the Treatment of Hyperkalemia
Introduction
Jeff Gilmore is an accomplished inventor based in Broomfield, Colorado. He has made significant contributions to the field of medical treatments, particularly in the management of hyperkalemia. With a total of two patents to his name, Gilmore's work focuses on innovative solutions that address critical health issues.
Latest Patents
Gilmore's latest patents include a novel microporous zirconium silicate designed for the treatment of hyperkalemia. This invention relates to compositions that effectively remove toxins, such as potassium ions, from the gastrointestinal tract at an elevated rate. Importantly, these formulations are designed to avoid undesirable side effects, such as an increase in urine pH or the potential entry of particles into the bloodstream. Additionally, the patent discloses a method for preparing high purity crystals of UZSi-9, which exhibit an enhanced level of potassium exchange capacity. These compositions are particularly beneficial in the therapeutic treatment of hyperkalemia.
Career Highlights
Jeff Gilmore is associated with Zs Pharma, Inc., where he continues to develop innovative medical solutions. His work has been instrumental in advancing treatments that improve patient outcomes in the management of hyperkalemia.
Collaborations
Some of his notable coworkers include Donald Jeffrey Keyser and Alvaro F Guillem. Their collaborative efforts contribute to the ongoing research and development in the field of medical treatments.
Conclusion
Jeff Gilmore's contributions to the treatment of hyperkalemia through his innovative patents highlight his commitment to improving healthcare solutions. His work exemplifies the impact of inventive thinking in addressing critical medical challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile